Activation of the mitogen-activated protein kinase (MAPK) cascade in mammalian cell lines positively regulates the G2/M transition. The molecular mechanism underlying this biological phenomenon remains poorly understood. Ribosomal S6 kinase (RSK) is a key downstream element of the MAPK cascade. Our previous studies established roles of RSK2 in Cdc25C activation during progesterone-induced meiotic maturation of Xenopus oocytes. In this study we demonstrate that both recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylate all three isoforms of human Cdc25 at a conserved motif near the catalytic domain. In human HEK293 and PC-3mm2 cell lines, RSK preferentially phosphorylates Cdc25A and Cdc25B in mitotic cells. Phosphorylation of the RSK sites in these Cdc25 isoforms increases their M-phase-inducing activities. Inhibition of RSK-mediated phosphorylation of Cdc25 inhibits G2/M transition. Moreover, RSK is likely to be more active in mitotic cells than in interphase cells, as evidenced by the phosphorylation status of T359/S363 in RSK. Together, these findings indicate that RSK promotes G2/M transition in mammalian cells through activating phosphorylation of Cdc25A and Cdc25B.
INTRODUCTION
Proliferation of somatic cells in higher eukaryotes depends on the presence of external mitogens, which activate corresponding receptors present on the plasma membrane. A common downstream event of these receptor activations is the activation of the mitogen-activated protein kinase (MAPK) cascade by Ras. [1] [2] [3] [4] A typical MAPK cascade comprises three sequential protein kinases RAF, MEK and ERK. A critical mediator of ERK functions is the 90-kDa ribosomal S6 kinase (RSK). [5] [6] [7] Previous studies demonstrated that both ERK and RSK promote cell cycle entry of quiescent cells and G1/S transition of cycling cells through transcriptional activation of cyclin D expression and inactivation of the RB family pocket proteins by G1-Cdk. [8] [9] [10] [11] [12] [13] [14] [15] In addition to these well-understood G1 phase functions of the MAPK cascade, accumulating evidence indicates that activation of the MAPK cascade also positively regulates the G2/M transition in somatic cell cycles. For example, cycling cells were found to activate the MAPK cascade in a biphasic manner, first in G1/S and then in G2/M phases. [16] [17] [18] Inhibiting this cascade inhibited or delayed the G2/M transition in cycling cells [19] [20] [21] and the G2-checkpoint recovery in DNA-damaged cells. 22 Increased activation of the MAPK cascade by ectopic expression of an oncogenic RAS produced opposite effects. 23 In RB family proteins (RB, p107 and p130) triple knockout mouse embryonic fibroblasts, which no longer require growth factors for passing the G1-phase restriction point, serum starvation activates the secondary G2-phase restriction point. In these cells, serum stimulation of cell cycle re-entry from G2 arrest requires activation of the MAPK cascade. 24 These findings predict that the MAPK pathway targets key components in the regulatory network that controls G2/M transition.
Similar to the G2-restriction point-arrested mammalian cells, Xenopus oocytes (stage VI) are naturally arrested at the G2/M boundary of the first meiotic division, and resumption of meiotic cell cycles requires mitogen stimulation and activation of the MAPK cascade. Under physiological conditions, progesterone stimulation of fully grown Xenopus oocytes releases the G2 phase arrest by activating mitotic Cdk 25 and the process involves activation of the MAPK cascade by newly synthesized protein kinase MOS, which, in turn, activates MEK. [26] [27] [28] [29] Because of the similarity in the linkage of the MAPK cascade to the regulation of G2/M transition, delineating the molecular mechanism by which the MAPK cascade promotes the G2/M transition in progesteronestimulated Xenopus oocytes may provide novel mechanistic insights into how this cascade positively regulates the G2/M transition in somatic cell cycles.
Three molecular mechanisms have been unraveled through which activation of the MAPK cascade positively regulates the G2/M transition in progesterone-stimulated Xenopus oocytes. The first involves RSK-mediated phosphorylation and inactivation of Myt1, 30 the protein kinase in Xenopus oocytes that inactivates the Cdk1/cyclin B complex by catalyzing inhibitory phosphorylations on Cdk1. 31 The second involves ERK1/2-mediated phosphorylation of Cdc25C, 32 the protein phosphatase in Xenopus oocytes that activates the Cdk1/cyclin B complex through removing the inhibitory phosphorylations on Cdk1. [33] [34] [35] The third involves activation of Cdc25C by RSK2; 36 RSK2 is the major RSK isoform in Xenopus oocytes. 37 As many of the biochemical regulations regulating meiotic cycles of Xenopus oocytes also occur in mitotic cycles of mammalian cells, 38 the three mechanisms described above suggest the possibility that activation of the MAPK cascade positively regulates G2/M transition in mammalian cells through phosphorylation of Cdc25 and Myt 1 by ERK and/or RSK family members. However, only the ERK-mediated phosphorylation of Cdc25C has been demonstrated to promote G2/M transition in mitotic cycles of mammalian cells. 32 Whether RSK phosphorylates Cdc25 and/or Myt 1 in mammalian cells has not been determined. The previous finding that mouse oocyte maturation does not require RSK function 39 makes it possible that RSK is not involved in Cdc25 and Myt1 regulations in mammalian cells.
In this study we characterized the role of RSK in the phosphorylation and activation of human Cdc25 (hCdc25) isoforms in human cell lines. Our results provide evidence that RSK plays an important role in the phosphorylation and activation of hCdc25A and hCdc25B in the process of G2/M transition.
RESULTS
Recombinant RSK phosphorylates A, B and C isoforms of hCdc25 in a conserved motif near the catalytic domain Among the numerous potential RSK phosphorylation sites in xCdc25C, RSK2 predominantly phosphorylates S317, T318 and/or S319 in the motif 313 KRRRSTS 319 . 36 Pairwise alignment of hCdc25A, hCdc25B and hCdc25C with xCdc25C showed that RSK2 phosphorylation sites in xCdc25C localize in a conserved region near the catalytic domain ( Figure 1a ). Within this conserved region, all three hCdc25 isoforms contain a string of basic residues that align with the string of basic residues in xCdc25C. Following the basic residue string, there are two Ser residues in hCdc25A (S293 and S295), one Ser residue and one Thr residue in hCdc25B (S353 and T355), and one Ser residue in hCdc25C (S247). These Ser/Thr residues align with the identified RSK2 phosphorylation sites in xCdc25C (Figure 1b) . The sequence conservation suggests that RSK phosphorylates multiple isoforms of hCdc25 at this conserved motif.
To test this possibility, we first incubated comparable amounts of GST-tagged hCdc25A, hCdc25B or hCdc25C (1-2 mg) with a constitutively active murine RSK (CA-RSK) for 30 min in the presence of g-32 P-ATP. GST-xCdc25C was used as a positive control. As shown in Figure 1c , CA-RSK catalyzed similar or higher levels of 32 P-incorportation into GST-hCdc25A, GST-hCdc25B and GST-hCdc25C as compared with the positive control. We then mutated Ser293 and Ser295 in hCdc25A to Ala293/Ala295 (2A), Ser353 and Thr355 in hCdc25B to Ala353/Val355 (AV), and Ser247 in hCdc25C to Ala247 (1A), and determined the effect on CA-RSKcatalyzed phosphorylations. As shown in Figure 1d , these mutations greatly reduced the CA-RSK-mediated phosphorylation of hCdc25 isoforms. Together, these results demonstrate that purified RSK is able to phosphorylate the conserved motif in all three isoforms of hCdc25.
Recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylates all of the predicted RSK sites in hCdc25 isoforms To further characterize the RSK phosphorylation sites in hCdc25 isoforms, we generated five phosphospecific antibodies (Table S1) and immunoblotted the wild type and phosphodefective mutant forms of GST-Cdc25 proteins that had been phosphorylated with CA-RSK. For GST-hCdc25A, the antibody for phosphorylated S293 (A-pS293 antibody) specifically reacted with the wild-type protein phosphorylated by CA-RSK (Figure 2a ). Similar results were obtained when the antibody for phosphorylated S295 (A-pS295 antibody) or for phosphorylated S293-S295 (A-pS293-pS295 antibody) was used in immunoblotting (Figures 2b and c) . For GST-hCdc25B, the antibody for phosphorylated S353 (B-pS353 antibody) specifically reacted with the wild-type protein phosphorylated by CA-RSK (Figure 2d ). Similar results were obtained when the antibody for phosphorylated T355 (B-pT355 antibody) was used in immunoblotting ( Figure 2e ). For GST-hCdc25C, the antibody for phosphorylated S247 (C-pS247 antibody) preferentially reacted with the wild-type protein phosphorylated by CA-RSK (Figure 2f ). In addition, we phosphorylated the wild GSTCdc25 proteins with M phase-arrested Xenopus egg extracts (MEE, 10 mg/ml), which contain high levels of activated RSK1/2.
37 By immunoblotting phosphorylated substrates with above-described phosphospecific antibodies, 1:5-diluted MEE readily phosphorylated hCdc25 isoforms at all of the characterized RSK sites in a 30-min incubation (Supplementary Figure S1 ). These results demonstrate that both recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylate all of the putative RSK sites in hCdc25 isoforms. The RSK sites in hCdc25A and hCdc25B are preferentially phosphorylated in mitotic cells To characterize RSK-mediated phosphorylation of Cdc25 in mammalian cells, we first determined whether phosphorylation of the RSK sites in hCdc25 isoforms is an M-phase-associated event. Human embryonic kidney HEK293 cells (transformed) and human prostate cancer PC-3mm2 cells (metastatic) were either growing asynchronously (B5% cells in mitosis) or being synchronized in mitosis by a thymidine block followed by a nocodazole block (480% cells in mitosis). After denatured extracts of random (R) and mitotically synchronized (M) cells were biochemically verified by immunoblotting with the mitotic phosphoprotein monoclonal antibody MPM-2 (Figures 3a and b), 40 phosphorylation of hCdc25 isoforms at the RSK sites was determined by immunoblotting with phosphospecific antibodies. We should note that HEK293 cells expressed all three isoforms of hCdc25, whereas PC-3mm2 cells only expressed detectable levels of hCdc25A and hCdc25B (data not shown).
For hCdc25A, S293 phosphorylation was readily detectable only in M cell extracts (Figures 3c and d) . In contrast, the hCdc25A protein level was similar in between R and M extracts of PC-3mm2 cells. Although the level of hCdc25A protein was 2-to 3-fold higher in M than in R extracts of HEK293 cells, this difference could not account for a B10-fold difference in the level of S293-phosphorylated hCdc25A. For hCdc25B, S353 phosphorylation was also readily detectable only in M cell extracts. In this case, the level of hCdc25B protein was similar in between R and M cell extracts for both cell lines (Figures 3e and f) . For hCdc25C, S247 phosphorylation was detected at borderline levels in both R and M extracts of HEK293 cells despite the presence of readily detectable levels of hCdc25C protein (data not shown). These results indicate that the RSK sites in hCdc25A and hCdc25B, but not in hCdc25C, are preferentially phosphorylated in mitotic cells.
To further examine this possibility, we incubated GST-hCdc25A, GST-hCdc25B or GST-hCdc25C with different dilutions of non-denatured mitotic extracts (ME) for 30 min and determined the RSK-site phosphorylation by immunoblotting with phosphospecific antibodies (Supplementary Figure S2) . For both HEK293 and PC-3mm2 cells, even 1:64-diluted ME readily phosphorylated GST-hCdc25A and GST-hCdc25B at the RSK sites. In contrast, only undiluted ME from HEK293 cells phosphorylated S247 in GSThCdc25C, and no phosphorylation of GST-hCdc25C at S247 was detected with undiluted ME from PC-3mm2 cells. These results support the preferential phosphorylation of the RSK sites in hCdc25A and hCdc25B in mitotic cells. Phosphorylation of the RSK sites in hCdc25A and hCdc25B increases their M-phase-inducing activities To determine the functional impact of RSK-mediated phosphorylation of hCdc25A and hCdc25B, we injected the wild type and RSKsite mutant forms of myc-tagged hCdc25A or hCdc25B and compared their abilities to induce Xenopus oocyte maturation. 32, 41, 42 For myc-hCdc25A, the phosphodefective mutant induced B50% oocyte maturation with a 1-h delay as compared with the wild-type molecule (Supplementary Figure S3A) . In contrast, the phosphomimetic mutant induced oocyte maturation at similar rates as the wild-type molecule (Supplementary Figure S3B) . For myc-hCdc25B, the wild-type protein induced B50% oocyte maturation at 4 h, whereas the phosphodefective mutant induced B50% oocyte maturation at 8 h (Supplementary Figure S3C) . Again, the phosphomimetic mutant acted similarly to the wild-type protein (Supplementary Figure S3D) . These results demonstrate that phosphorylation of the RSK sites in hCdc25A and hCdc25B increases their M-phase-inducing activities.
To further examine this observation, we ectopically expressed similar levels of the wild type and RSK-site mutant forms of hCdc25A or hCdc25B in S-phase-arrested HEK293T cells (Figure 4a ) and compared their abilities to induce unscheduled mitotic entry, also called PCC (premature chromosome condensation). 43 HEK293T cells were chosen for this experiment because B90% of transfected cells expressed transgenes. Cells in the PCC state were identified by their round cell morphology, which had been predetermined by nuclear staining to closely correlate with chromosome condensation (data not shown). Figure 4b shows representative results from ectopic expression of different forms of FLAG-hCdc25A. Vector-transfected cells had B4% in the PCC state. This population increased by 48-fold in cells expressing FLAG-hCdc25A and by 410-fold in cells expressing the phosphomimetic form of FLAG-hCdc25A. However, in cells expressing the phosphodefective form of FLAG-hCdc25A, the PCC population only increased by threefold. Figure 4c shows representative results from ectopic expression of different forms of FLAG-hCdc25B. Again, the wild type or phosphomimetic form of the protein was much more effective than the phosphodefective form of the protein in inducing PCC in S-phase-arrested cells. Figure 4d shows representative phase-contrast images of live cells expressing different forms of FLAG-hCdc25B. These results support the conclusion from oocyte maturation assays that phosphorylation of the RSK sites in hCdc25A and hCdc25B increases their M-phaseinducing activities.
RSK is one of the major kinases in mitotic cell lysates that phosphorylate the RSK sites in hCdc25A and hCdc25B Aurora kinase A was previously shown to phosphorylate S353 of hCdc25B at centrosomes at the onset of mitosis. 44, 45 Other AGC family protein kinases in mitotic cells may also phosphorylate the RSK sites in hCdc25 isoforms due to their similar phosphorylation acceptor sites. 46, 47 To characterize the contribution of RSK to the mitotic phosphorylation of hCdc25A and hCdc25B at the RSK sites, we phosphorylated GST-hCdc25A and GST-hCdc25B with M extracts (MEs) from HEK293 or PC-3mm2 cells in the presence or absence of the RSK2 inhibitor BI-D1870 or SL0101, and immunoblotted the substrates with phosphospecific antibodies; phosphorylation of the same substrates with Xenopus MEE served as a positive control.
In 1:30-diluted ME from HEK293 cells, 2 mM of BI-D1870 or 40 mM of SL0101 caused a B50% reduction in the phosphorylation of GST-hCdc25A at S293 (Figures 5a and b) and of GST-hCdc25B at S353 (Figures 5c and d) . Similar results were obtained when the phosphorylation was performed with 1:60-diluted ME from PC3mm2 cells or 1:20-diluted Xenopus MEE (data not shown). However, no inhibition was observed when the phosphorylation was performed with undiluted ME or MEE (data not shown). These results indicate that RSK is one of the major kinases in mitotic and meiotic cell lysates that phosphorylate the RSK sites in hCdc25A and hCdc25B.
RSK-mediated phosphorylation of hCdc25 has a positive role in G2/M transition In our initial effort to determine the role of RSK-mediated phosphorylation of Cdc25 in the regulation of G2/M transition, we characterized the effect of the two RSK inhibitors on G2/M transition and hCdc25A phosphorylation in HEK293 and PC-3mm2 cells. Cells were first arrested in S phase by thymidine and then released in the presence of the mitotic blocker nocodazole. By examination of cell morphology (data not shown) and by MPM-2 immunoblotting over time, (upper panels of Figures 6a-d) both BI-D1870 and SL0101 inhibited G2/M transition in both HEK293 and PC-3mm2 cells. These effects coincided with inhibition of the phosphorylation of hCdc25A at S293 (lower panels of Figures 6a-d) . The effect of BI-D1870 on the G2/M transition was also examined in HEK293 or PC-3mm2 cells without a prior thymidine block. Again, by both MPM-2 immunoblotting and phase-contrast microscopy, BI-D1870 inhibited mitotic entry in both HEK293 and PC-3mm2 cells (data not shown), indicating that the inhibitory effect of RSK inhibitors on G2/M transition did not depend on a prior S-phase block. To complement the inhibitor studies, we then transfected PC-3mm2 cells with four different combinations of RSK1 and RSK2 siRNAs and determined the effect on G2/M transition after releasing the S-phase block. As RSK3 is also widely expressed in human cell lines, 5, 7, 48 this RNAi approach should cause only a partial RSK inhibition. For each combination of siRNAs used, both RSK1 and RSK2 expressions were knocked down by 480% and the mitotic entry at 24 h was partially inhibited as determined by MPM-2 immunoblotting (Supplementary Figure S4) . Consistent with each other, these results demonstrate that RSK has a positive role in G2/M transition.
RSK is known to have a variety of biological functions. To determine whether promoting Cdc25 activation is at least one of the major mechanisms through which RSK promotes G2/M transition, we ectopically expressed the wild type or RSK sitedefective or -mimetic mutant forms of FLAG-hCdc25B in S-phasearrested HEK293T cells and compared their abilities to counteract the inhibitory effect of BI-D1870 on the subsequent G2/M transition. As nonphosphorylated Cdc25B has a basal level of the phosphatase activity, all three forms of FLAG-hCdc25B were expected to have some rescuing effects. However, if promoting Cdc25 activation is a major mechanism through which RSK promotes G2/M transition, the phosphomimetic form of FLAG-hCdc25B should be more potent than the other two forms of the molecule in rescuing the inhibitory effect of BI-D1870.
We observed mitotic entry at B7 h after releasing the S-phase arrest in control cells. As shown in Figure 7a , B50% of nontransfected cells had entered mitosis without the BI-D1870 treatment, whereas o10% of nontransfected cells had entered mitosis with the BI-D1870 treatment, confirming the inhibitory effect of BI-D1870 on the G2/M transition. Strikingly, expression of the phosphomimetic form of FLAG-hCdc25B led to B80% of cells entering mitosis despite the presence of BI-D1870. In contrast, expression of the wild type or phosphodefective form of FLAGhCdc25B led to o40 or B20% of cells entering mitosis in the presence of BI-D1870. Immunoblot results presented in Figure 7b verified that the three forms of FLAG-hCdc25B were expressed at similar levels. Figure 7c shows representative images of live cells from phase-contrast microscopy. These results support the notion that phosphorylating hCdc25A and hCdc25B at the RSK sites is at least one of the major mechanisms through which RSK promotes G2/M transition.
One of the key activating sites in RSK is preferentially phosphorylated in mitotic cells Full activation of RSK1/2/3 requires phosphorylation of both S227 (numbering by RSK2) and S363 (numbering by RSK1) residues. 5, 7, 48 To examine the activation status of RSK in mitotic cells versus interphase cells, verified R and M extracts from HEK293 ( Figures  8a-c) or PC-3mm2 cells (Figures 8d-f) were immunoblotted with antibodies that recognize either RSK1 and RSK2 proteins or their activating phosphorylations. For both HEK293 and PC-3mm2 cells, RSK1 and RSK2 proteins are expressed at similar levels in R and M cells. However, although the level of S227 phosphorylation was similar in R and M cells, the level of T359-S363 phosphorylation was greatly increased in M cells relative to R cells (Figures 8b  and e) . The T359-S363 phosphorylation of RSK was further confirmed by denaturing immunoprecipitation of RSK1-3 proteins from M extracts followed by immunoblotting with the T359-S363 phosphospecific antibodies (Figures 8c and f) . Interestingly, the anti-RSK1-3 antibodies used did not immunoprecipitate T359-S363-phosphorylated RSK under nondenaturing conditions (data not shown). As a further support of mitotic-specific phosphorylation of T359-S363 in RSK, the T359-S363 phosphospecific antibodies preferentially stained mitotic cells in paraffin sections of PC-3mm2 cell xenograft tumors in nude mice (Supplementary Figure S5) . The combined results demonstrate for the first time that RSK may be more active in mitotic cells than in interphase cells.
DISCUSSION
RSK is a widely expressed downstream effector of the MAPK cascade. In this study we demonstrate that both recombinant RSK and RSK in Xenopus egg extracts phosphorylate all three isoforms of hCdc25 at a conserved motif near the catalytic domain. In human cell lines, RSK preferentially phosphorylates Cdc25A and Cdc25B in mitotic cells. Phosphorylation of the RSK sites in hCdc25A and hCdc25B increases their M-phase-inducing activities. RSK-mediated activation of Cdc25 has a positive role in G2/M transition. Moreover, RSK is likely to be more active in mitotic cells than in interphase cells. These findings identify a novel link between activation of the MAPK cascade and regulation of the G2/M transition. All three isoforms of Cdc25 can activate the mitotic Cdk complex during G2/M transition of mammalian cells. Previous studies have already identified multiple protein kinases that activate one or multiple isoforms of Cdc25 by phosphorylating unique sites. 49, 50 However, most of the identified kinases activating Cdc25 in mitotic cells are either the substrates of Cdc25 (for example, Cdk1 or Cdk2 complexes) or kinases that are activated downstream of Cdks (for example, Plk1 or Aurora kinases). Although these kinases are able to enhance Cdc25 activation by a feed-forward mechanism, they may not have important roles in initiating Cdc25 activation before Cdk activation. Our previous results demonstrated that ERK preferentially phosphorylates and activates hCdc25C in mitotic cells. 32 As ERK activation does not depend on the activation of mitotic Cdk, we hypothesize that ERK is one of the initiating kinases for hCdc25C activation during G2/M transition. 36 Different from ERK, the results in this study show that RSK preferentially activates hCdc25A and hCdc25B during G2/M transition. It is thus conceivable that RSK may complement ERK in initiating Cdc25 activation during G2/M transition of mammalian cells.
During G2 phase, cells are meant to fulfill various requirements for entry into mitosis, including repairing DNA damage accumulated in earlier phases of the cell cycle. As inhibition of Cdc25 activation is the most critical event in maintaining cells in G2 phase before the requirements are properly fulfilled, [51] [52] [53] [54] abnormally high levels of Cdc25 expression or activation weaken the G2 checkpoint and promote abnormal mitosis and genetic instability in both cellular and animal models. [55] [56] [57] Importantly, the MAPK cascade is frequently overexpressed or overactivated in tumor cells due to a variety of mechanisms.
2 RSK1/2 protein is overexpressed in multiple types of human cancers. [58] [59] [60] As we now know that at least two components linked to the MAPK cascade directly activate Cdc25 during the G2/M transition, it is conceivable that hyperactivation of the MAPK cascade or RSK overexpression in tumor cells results in less-controlled Cdc25 activation and, as a result, weakens the G2 checkpoint. This hypothesis may explain why oncogenic activation of RAS promotes abnormal mitosis and genetic instability within one cell cycle, 61 and why this effect is greatly enhanced by overexpression of Cdc25A. 62 This hypothesis also raises the possibility that attenuation of Cdc25 activation by RSK inhibitors or partial inhibition of Cdc25 activity by Cdc25 inhibitors counteracts the genetic instability in tumor cells.
RSK comprises a family of structurally related kinases, consisting of RSK1, RSK2, RSK3 and RSK4. Among the four isoforms, RSK1, RSK2 and RSK3 are widely expressed in human tissues and cell lines, 5, 7, 48 and are likely to phosphorylate overlapping substrates.
Thus, RSK referred to in this study includes at least RSK1, RSK2 and RSK3. However, we are also aware that different isoforms of RSK may have different roles in certain aspects of cell regulation.
59,63
Thus, we cannot exclude the possibility that different isoforms of RSK contribute differently to the phosphorylation of hCdc25A and/ or hCdc25B during the G2/M transition. Clarification of this issue will require detailed analysis of different RSK isoforms in phosphorylating hCdc25A and hCdc25B in vitro and in vivo.
RSK contains an N-terminal kinase domain (NTK) responsible for the phosphorylation of substrates, a middle linker region and a C-terminal kinase domain (CTK) that activates NTK. Previous studies have demonstrated that full activation of RSK1-3 by the ERK bound to the C terminus of CTK requires two independent mechanisms. 5, 7, 48 One mechanism involves ERK-mediated phosphorylation of two adjacent conserved residues (T359 and Ser363 in RSK1) in the linker region of RSK, in which S363 phosphorylation directly activates the NTK. 64 In parallel, ERKmediated phosphorylation of a conserved residue (Thr577 in RSK2) in the CTK activates the CTK, which in turn phosphorylates a conserved residue (Ser380 in RSK1) in the linker region. The S380 phosphorylation results in the recruitment of 3-phosphoinositidedependent protein kinase 1, which then stimulates the NTK activity through phosphorylating a conserved residue (Ser227 in RSK2) in the NTK. On the basis of these previous studies, a fully activated RSK should have both S227 and S363 phosphorylated. Interestingly, although the level of the S227 phosphorylation is similar in between interphase and mitotic cells, the T359-Ser363 phosphorylation is readily detectable only in mitotic cells (Figures  8b and f) . These findings provide the first evidence that RSK1/2/3 may be more active in mitotic cells than in interphase cells. This possibility provides one plausible explanation as to why the RSK sites in hCdc25A and hCdc25B are preferentially phosphorylated in mitotic cells. We also observed that anti-RSK antibodies specifically could not immunoprecipitate T359-S363-phosphorylated RSK under nondenaturing conditions (data not shown), raising a possibility that the T359-S363 phosphorylation may induce a change in RSK conformation or partner protein interaction. Future studies will elucidate the mechanism by which the T359 and S363 are preferentially phosphorylated in mitotic cells and address the functional impact on the mitotic-specific phosphorylation of the RSK sites in hCdc25A and hCdc25B.
MATERIALS AND METHODS

In vitro phosphorylation of Cdc25 recombinant proteins
Preparations of GST-tagged CA-RSK and various Cdc25 recombinant proteins were described previously. 32, 36 RSK-site mutant forms of GSTtagged hCdc25 isoforms were produced by site-directed mutagenesis using ExSite PCR-based site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA). The GST-tagged Cdc25 recombinant proteins were expressed in E. coli BL-21 (Invitrogen, Grand Island, NY, USA) or Rosseta strain (Novagen, Billerica, MA, USA) and affinity absorbed onto glutathionesepharose (GE Healthcare, Pittsburgh, PA, USA). 32 The immobilized Cdc25 recombinant proteins were stored in 20% glycerol at À 80 1C until use. GST-hCdc25C was incubated with 10 mM dithiothreitol on ice for 30 min before being used in phosphorylation reactions. Preparation of cell lysates and in vitro phosphorylation of Cdc25 recombinant proteins were performed as described in Supplementary Materials.
Cell culture, treatment of cells with RSK inhibitors and cDNA transfection HEK293 or HEK293T cells were cultured in Dulbecco's modification of Eagle's medium (Mediatech Inc., Manassas, VA, USA) supplemented with 2 mM L-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA). PC-3mm2 cells were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum. Mitotic population of HEK293 and PC3-mm2 cells were obtained by a 12-to 16-h block with 2 mM thymidine (CALBIOCHEM, Billerica, MA, USA) followed by a 12-to 16-h block with 0.05 mg/ml nocodazole (CALBIOCHEM). Percentages of cells in mitosis were determined from three to five images taken under a phasecontrast microscope. BI-D1870 was chemically synthesized by The Translational Chemistry Core Facility at the MD Anderson Cancer Center or purchased from Exon Medchem (Groningen, NL, USA), and dissolved with dimethyl sulfoxide. SL0101 was purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada) These inhibitors were dissolved with dimethyl sulfoxide to make a 1000 Â stock based on the final concentration needed, and the stock solutions were stored at À 80 1C in small aliquots until use.
pCMV-Tag-2B-based mammalian expression vectors for FLAG-hCdc25A and FLAG-hCdc25B were produced by PCR amplification of the coding region for hCdc25A or hCdc25B, followed by subcloning of the coding region into pCMV-Tag-2B vector. These vectors were used as templates to generate expression vectors for the RSK-site mutant forms of FLAGhCdc25A or FLAG-hCdc25B through site-directed mutagenesis. HEK293T cells were transfected with these expression constructs or the parental vector by calcium phosphatase transfection method.
